A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma

作者：Abhijit Ray, Matthew A. Williams, Stephanie Meek, Randy C. Bowen, Kenneth F. Grossmann, Robert H.I. Andtbacka, Tawnya L. Bowles, John Hyngstrom, Sancy A. Leachman, Douglas Grossman, Glen M. Bowen, Sheri L. Holmen, Matthew W. VanBrocklin, Gita Suneja, Hung T. Khong · 发表于：Oncotarget · 年份：2016 · DOI：10.18632/oncotarget.10453 · 被引用次数：77 · 研究领域：Cancer Immunotherapy and Biomarkers、Immunotherapy and Immune Responses、Cutaneous Melanoma Detection and Management

// Abhijit Ray 1,* , Matthew A. Williams 2,* , Stephanie M. Meek 2 , Randy C. Bowen 3 , Kenneth F. Grossmann 1 , Robert H.I. Andtbacka 4 , Tawnya L. Bowles 5 , John R. Hyngstrom 4,5 , Sancy A. Leachman 6 , Douglas Grossman 1 , Glen M. Bowen 1 , Sheri L. Holmen 1 , Matthew W. VanBrocklin 1 , Gita Suneja 7 and Hung T. Khong 1 1 Division of Oncology, Huntsman Cancer Institute-University of Utah, Salt Lake City, UT, USA 2 Department of Pathology, University of Utah, Salt Lake City, UT, USA 3 School of Medicine, University of Utah, Salt Lake City, UT, USA 4 Section of Surgical Oncology, Division of General Surgery Huntsman Cancer Institute-University of Utah, Salt Lake City, UT, USA 5 Department of General Surgery, Intermountain Medical Center, Murray, UT, USA 6 Department of Dermatology, Oregon Health & Science University-Knight Cancer Institute, Portland, OR, USA 7 Department of Radiation Oncology, University of Utah, Salt Lake City, UT, USA * These authors have contributed equally to this work Correspondence to: Hung T. Khong, email: // Keywords : ipilimumab, interleukin-2, intratumoral, abscopal effect, immunotherapy Received : June 17, 2016 Accepted : June 25, 2016 Published : July 06, 2016 Abstract Purpose: Intratumoral interleukin-2 (IL-2) is effective but does not generate systemic immunity. Intravenous ipilimumab produces durable clinical response in a minority of patients, with potentially severe toxicities. Circulating anti-tumor T cells activated by ipilimumab may ...